An update on actively targeted liposomes in advanced drug delivery to glioma
| Autor: | Parvin Zakeri-Milani, Muhammad Sarfraz, Hadi Valizadeh, Salar Hemmati, Paul R. Walker, Yousef Fatahi, Masoud Farshbaf, Solmaz Mojarad-Jabali |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Aptamer
Pharmaceutical Science 02 engineering and technology Blood–brain barrier 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Drug Delivery Systems Targeted liposomes Glioma Cell Line Tumor Medicine Humans Liposome business.industry Brain Neoplasms Cancer 021001 nanoscience & nanotechnology medicine.disease medicine.anatomical_structure Blood-Brain Barrier Drug delivery Liposomes Cancer research Conventional chemotherapy 0210 nano-technology business |
| Zdroj: | International journal of pharmaceutics. 602 |
| ISSN: | 1873-3476 |
| Popis: | High-grade glioma is one of the most aggressive types of cancer with a low survival rate ranging from 12 to 15 months after the first diagnosis. Though being the most common strategy for glioma therapy, conventional chemotherapy suffers providing the therapeutic dosage of common therapeutics mostly because of limited permeability of blood–brain barrier (BBB), and blood–brain tumor barrier (BBTB) to anticancer agents. Among various nanoformulations, liposomes are considered as the most popular carriers aimed for glioma therapy. However, non-targeted liposomes which passively accumulate in most of the cancer tissues mainly through the enhanced permeation and retention effect (EPR), may not be applicable for glioma therapy due to BBB tight junctions. In the recent decade, the surface modification of liposomes with different active targeting ligands has shown promising results by getting different chemotherapeutics across the BBB and BBTB and leading them into the glioma cells. The present review discusses the major barriers for drug delivery systems to glioma, elaborates the existing mechanisms for liposomes to traverse across the BBB, and explores the main strategies for incorporation of targeting ligands onto the liposomes. It subsequently investigates the most recent and relevant studies of actively targeted liposomes modified with antibodies, aptamers, monosaccharides, polysaccharides, proteins, and peptides applied for effective glioma therapy, and highlights the common challenges facing this area. Finally, the actively targeted liposomes undergoing preclinical and clinical studies for delivery of different anticancer agents to glioma cells will be reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect